Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Caregen Co., Ltd. (214370.KQ)
Anyang-si, KR
Caregen Co., Ltd. is primarily involved in the creation and development of biomimetic peptides. The company operates through distinct business segments, each catering to specific markets. Its Professional Therapy division engineers medical devices utilizing functional peptides and sophisticated sustained-release technology. Through its Cosmeceutical line, Caregen offers a variety of products for skin and hair care, including solutions for whitening, anti-inflammatory purposes, and those mimicking botulinum toxin functions. The Health Functional Food division provides dietary supplements specifically designed for blood control. Additionally, the Raw Material segment supplies essential peptide growth factors. Founded on August 17, 2001, the firm is headquartered in Anyang-si, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.12% | -2.10% | -16.21% | -35.38% | +1.26% | +19.78% | +172.84% | +138.53% | +550.96% | +287.38% | +313.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-11.8% Q1'26: +6.6% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-25.0% Q1'26: +39.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+26.5% ★ Q1'26: +38.7% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+35.1% ★ Q1'26: +44.6% (vs Q1'25)
-
ROIC Chemicals: +3.4%+12.2% ★ Q1'26: +20.5% (vs Q1'25)
-
Share dilution Chemicals: +0.0%-0.5% ★ Q1'26: +9.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
79.21B
est: 98.00B (-19.2%)
|
82.59B
est: 82.00B (+0.7%)
|
72.81B
est: 27.20B (+167.7%)
|
119.00B
119.00B – 119.00B
+337.5% YoY
|
| EBITDA |
45.36B
est: 52.16B (-13.0%)
|
39.41B
est: 40.13B (-1.8%)
|
25.56B
est: 13.31B (+92.0%)
|
58.24B
58.24B – 58.24B
+337.5% YoY
|
| EBIT |
40.38B
est: 47.37B (-14.8%)
|
34.25B
est: 36.70B (-6.7%)
|
25.56B
est: 12.17B (+110.0%)
|
53.25B
53.25B – 53.25B
+337.5% YoY
|
| Net Income |
39.93B
est: 36.86B (+8.3%)
|
32.31B
est: 35.72B (-9.5%)
|
24.12B
est: 40.02B (-39.7%)
|
60.86B
60.86B – 60.86B
+52.1% YoY
|
| SGA |
4.22B
est: 6.03B (-30.0%)
|
5.32B
est: 10.00B (-46.8%)
|
26.69B
est: 3.32B (+704.2%)
|
14.52B
14.52B – 14.52B
+337.5% YoY
|
| EPS |
813.00
est: 750.00 (+8.4%)
|
657.47
est: 730.00 (-9.9%)
|
493.00
est: 818.00 (-39.7%)
|
1,244.00
1,244.00 – 1,244.00
+52.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 214370.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
